Breast Cancer

A study of 922 patients shows the Aida test predicts 10-year recurrence risk and helps guide radiation decisions for invasive breast cancer.

A structured exercise program may reduce cognitive decline, often referred to as “chemo brain,” in patients receiving chemotherapy for the first time.

Preliminary INVINCIBLE-4 study data shows INT230-6 plus standard care may increase pathological complete response rates and improve patient safety.

During the Miami Breast Cancer Conference, CURE discussed ADCs with Dr. Kevin Kalinsky.

Dr. Kevin Kalinsky discusses common side effects associated with the FDA-approved combination of Enhertu and Perjeta for breast cancer.

The phase 3 persevERA study of giredestrant plus Ibrance missed its PFS goal, though positive data from other trials supports the drug.

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for patients with TNBC.

FDA grants priority review to Enhertu for patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment.

Clinical trial data show a carboplatin-free regimen offers similar results with fewer side effects for patients with stage 2 to 3 HER2+ disease.

Zovegalisib plus Faslodex elicited responses in patients with HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer.

Here are five key takeaways regarding the use of GLP-1 receptor agonists in patients who are undergoing breast cancer treatment.

At the Miami Breast Cancer Conference, Dr. Heather A. Parsons shared growing evidence for the prognostic value of circulating tumor DNA.

New data show that Enhertu had similar safety in the real world as in clinical trials in patients with HER2-low metastatic breast cancer.

A community study finds Enhertu effective for HER2-low mBC, with over half of patients seeing tumor shrinkage and high one-year survival rates.

New data show more women over 70 are safely skipping sentinel lymph node biopsies for HR+ breast cancer, reducing unnecessary surgery and risks.

After abnormal mammogram, family history and testing revealed a BRCA1 mutation, leading one woman to choose preventive surgeries and share her experience.

Transitioning into survivorship and relocating to a new city prompts reflection on identity, fear and freedom, showing survivorship as choosing to live forward.

March weather becomes a metaphor for survivorship as a mother describes anxiety, relief and uncertainty patients with cancer feel between scans.

The bispecific ADC izalontamab brengitecan improved survival for patients with metastatic triple-negative breast cancer in a Phase 3 clinical trial.

Lauren Yerkes shares how her breast cancer diagnosis uncovered generations of genetic information for her family.

My daughter is happy to tell her story so that others can learn that there is hope in the face of despair.

The FDA granted fast track status to ART6043 plus Lynparza for patients with gBRCA-mutated HER2-negative breast cancer to accelerate drug development.

Dr. William Audeh discusses how genomic subtyping can close the 38% mortality gap for Black women by identifying aggressive basal-type cancers.

Genentech announces FDA acceptance of giredestrant plus Afinitor for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer treatment.

Dr. Sara Tolaney discusses how Trodelvy plus Keytruda improves progression-free survival in patients with PD-L1+ metastatic triple-negative breast cancer.